



RECEIVED

DEC 09 2002

TECH CENTER 1600/2900

#8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bernd Riedl et al.

Serial No.: 10/042,226

Group Art Unit: 1614

Filed: January 11, 2002

Examiner: James Reamer

For:  $\omega$ -CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98**

Assistant Commissioner for Patents  
Washington, D. C. 20231

Sir:

Based on information from foreign associates, it is believed that at least Iranian No. 26555 and Lebanese No. 6124 are patented applications filed in the English language and registered. Copies of the registration certificates and the applications filed are provided herewith.

Iran Patent No. 26555 was filed on January 13, 2000 and Lebanese Patent No. 6124 was filed on January 12, 2000. Both filing dates are within one year of the effective filing date of this application.

FEES

No fee is required for this Information Disclosure Statement because:


This Information Disclosure Statement is being filed before the mailing of a first action on the merits after the filing of a Request for Continued Examination Under §1.114.

DEPOSIT ACCOUNT

The Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-

3402, two copies of this paper are attached for this purpose.

Respectfully submitted,




Richard J. Traverso (Reg. No. 30,595)  
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1  
2200 Clarendon Blvd. Suite 1400  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER 24A

Date: **December 6, 2002**

RJT:lvb  
K:\Bayer\24A\IDS 12-6-02.dot



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

**Complete if Known**

Application Number	10/042,226
Filing Date	January 11, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1614
Examiner Name	James Reamer
Attorney Docket Number	BAYER 24A

## U.S. PATENT DOCUMENTS

RECEIVED

DEC 09 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

**Examiner  
Signature**

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

DEC 09 2002

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 5

**Complete if Known**

Application Number	10/042,226
Filing Date	January 11, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1614
Examiner Name	James Reamer
Attorney Docket Number	BAYER 24A

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Publication No. US 2002/0065296 A1, Publication Date: May 30, 2002, Dumas et al.	
		Publication No. US 2002/0062763 A1, Publication Date: May 30, 2003, Macholdt et al.	
		Publication No. US 2002/0128321 A1, Publication Date: September 21, 2002, Widdowson et al.	
		Publication No. US 2002/0082255 a1, Publication Date: June 27, 2002, Eastwood	
		Caplus 113:106314, Abstract of JP 2022650, Silver halide color photographic material containing a cyan coupler of 2-ureido-phenol type to improve dye developability and remove leuco cyan dye, Noboru Mizukura et al. January 25, 1990.	
		Caplus 113:142130, Abstract of JP 2023337, Silver halide photographic material containing phenolic cyan coupler a colorless cyan coupler, Toshihiko Yagi et al., January 25, 1990.	
		Caplus 87:62295, "The metabolism and toxicity of halogenated carbanilides. Biliary metabolites of 3,4,4'-trichlorocarbanilide and 3-trifluoromethyl-4,4'-dichlorocarbanilide in the rat", Chemical Life Science, pp. 157-66, 1977.	
		Caplus 127:293717, "Optical properties of segmented oligourethane with azomethine terminal fragments", National Academy of Science of Ukraine, M. V. Kurik et al., pp. 2038-2041, 1996.	
		Caplus 127:273945, "Quantitative structure-biodegradability studies: an investigation of the MITI aromatic compound database", School of Pharmacy and Chemistry, J. C. Dearden, pp. 93-104, 1996	
		Caplus 126:166148, "Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells", James D. Winkler et al., J. Pharmacol. Exp. Ther. Pp. 956-966, 1996.	
		Caplus 98:78152, Abstract of JP 57185219, "Antitumor benzophenone derivatives", November 15, 1982.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/vb:K:\Bayer\24A\PTO-1449 12-6-02.dot

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	5
-------	---	----	---

**Complete if Known**

Application Number	10/042,226
Filing Date	January 11, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1614
Examiner Name	James Reamer
Attorney Docket Number	BAYER 24A

## U.S. PATENT DOCUMENTS

[illegible]

RECEIVED  
DEC 09 2002  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office 3	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		EP	0192263B1			8-27-1986		
		EP	0107214A1			5-2-1984		
		WO	0047577			8-17-2000		
		WO	99/21835			5-6-1999		
		WO	99/24635			5-6-1999		
		WO	00/41698			7-20-2000		
		WO	00/42012			7-20-2000		
		WO	01/36403A1			5-25-2001		
		WO	96/13632			5-9-1996		
		WO	99/20617			4-29-1999		
		WO	96/13632			5-9-1996		
		WO	02/24635A2			3-28-2002		
		IR	26555					
		LB	6124					

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 Of 5

### Complete if Known

Application Number	10/042,226
Filing Date	January 11, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1614
Examiner Name	James Reamer
Attorney Docket Number	BAYER 24A

RECEIVED

DEC 09 2002

TECH CENTER 1600/2900

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Caplus 72:79046, Abstract of CH 479557, "Tuberculostatic and cancerostatic polybasic ureas", Dr. A. Wander, October 15, 1969.	
		Caplus 125:245169, "Production of murine monoclonal antibodies against sulcofuron and flucofuron by in vitro immunization", G. A. Bonwick et al., J. Immunol. Methods, pp. 163-173, 1996.	
		Caplus 127:34137f, "Preparation of quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation", Kazuo Kubo et al., May 15, 1997.	
		Caplus 131:58658, "Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas", Miller, Scott, July 1, 1999.	
		Caplus 131:87909y, "Inhibition of p38 kinase activity using substituted heterocyclic ureas", Jacques Dumas, July 1, 1999.	
		Caplus 131:73649b, "Preparation of pyrazolyl aryl ureas and related compounds as p38kinase inhibitor", Jacques Dumas, July 1, 1999.	
		Joseph V. Simone, "Cecil Textbook of Medicine", 20th Edition, Vol. 1, 2-3-1997. pp. 1004-1010.	
		Cesar Raposo et al., "Catalysis of Nucleophilic Addition of Pyrrolidine to 2-(5H)-Furanone through Chromenone Cleft-Type Receptors", Vol. 37, No. 38, pp. 6947-6950, 1996.	
		Jacqueline E. van Muijwijk-Koezen et al., "Isoquinoline and Quinazoline Urea Analogues as Antagonists for the Human Adenosine A <sub>3</sub> Receptor", J. Ed. Chem. 2000, 43, pp. 2227-2238, January 3, 2000.	
		Jacques Dumas et al., "1-Phenyl-5-pyrazolyl Ureas: Potent and Selective p38 Kinase Inhibitors", Bioorganic & Medicinal Chemistry Letters, pp. 2051-2054, May 2, 2000.	
		Robert W. Carling et al., "1-(3-Cyanobenzyl)piperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one: A Selective High-Affinity Antagonist for the Human Dopamine D <sub>4</sub> Receptor with Excellent Selectivity over Ion Channels", J. Med. Chem., 1999, 42, pp. 2706-2715.	
		Abstract WO 9822103, May 28, 1998, John Philip Hedge et al.	

Examiner  
Signature

Date  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb:K:\Bayer\24A\pg. 3 PTO-1449 12-6-02.dot

